glp-1 drugs and muscle loss GLP-1R agonists use | Acta Diabetologica Weight loss with GLP-1 medicines

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake

We report an unusual case of diabetic ketoalkalosis, a mixed acid-base disorder, in a 57-year-old female patient with insulin-dependent T2DM following a switch to Mounjaro (tirzepatide)

Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis